TY - T1的长效anti-muscarinic代理(喇嘛)的使用频率和严重哮喘患者的临床特征真实设置:在意大利严重哮喘的数据网络(便)注册JF -欧洲呼吸杂志》乔和J - 10.1183/13993003.国会2019欧元。PA4255六世- 54 - 5 63 SP - PA4255 AU -弗朗西斯卡Puggioni盟Enrico马可Heffler AU -乔治•沃尔特Canonica盟曼Latorre AU -弗朗西斯科·布拉西盟Pierluigi Paggiaro AU -马可Caminati盟Gianenrico塞纳Y1 - 2019/09/28 UR - //www.qdcxjkg.com/content/54/suppl_63/PA4255.abstract N2 -背景:不受控制的哮喘患者尽管高剂量吸入激素加上另一个控制器被定义为严重的哮喘患者。溴化Tiotropium Respimat是唯一长期代理毒蕈碱的受体激动剂(喇嘛)批准的严重哮喘。目的:探讨严重哮喘患者治疗的频率与喇嘛和描述一个真实的临床特征,基于注册设置。方法:在意大利严重哮喘的基线数据网络(便)注册中心进行了分析研究使用的喇嘛和可能的严重哮喘患者临床特征相关。结果:在698登记的病人中,35.9%服用喇嘛(溴化Tiotropium Handihaler Tiotropium溴Respimat 23.3%, 4.5%, 4.5% Aclidinium,格隆溴铵0 3.4%,3%溴化umeclidinium)。病人服用喇嘛有更高的哮喘发病年龄(35.3 vs 32.4, p = 0.045)和更频繁的前吸烟者(26.6%比17.5%,p = 0.001)。他们年恶化率较高(3.9 vs 2.4, p = 0.004),严重的哮喘控制的行为:17.2 vs 18.4, p = 0.012;ACQ: 2.88 vs 2.47, p = 0.008),严重的疾病相关的生活质量(AQLQ: 4.24 vs 4.69, p = 0.001)和肺功能较差(FEV1%: 70.26%比75.48%,p = 0.007)。支气管扩张是更频繁地发现在喇嘛用户(25.9%比13.1%,p = 0.001)。 Patients taking LAMAs were also more frequently treated also with biologicals (64.4% vs 54.5%, p=0.011).Conclusions: Tiotropium bromide is still underused in severe asthma in a real-life setting. Patients taking LAMAs have features of the most severe asthmaticsFootnotesCite this article as: European Respiratory Journal 2019; 54: Suppl. 63, PA4255.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -